UNBS 5162 is in a Phase I study for solid tumors and lymphoma.
Drais Pharmaceuticals licensed Unibioscreen’s early-stage cancer drug in a deal valued at over $31 million. The agreement grants Drais exclusive rights to develop and commercialize UNBS 5162 worldwide.
The $31 million covers an upfront payment as well as development and regulatory milestones fees. Drais will also pay milestones dependant on commercialization.
UNBS 5162 is a naphthalimide in Phase I trials for the treatment of solid tumors and lymphoma.